A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus

NCT03616912 · clinicaltrials.gov ↗
PHASE3
Phase
TERMINATED
Status
830
Enrollment
INDUSTRY
Sponsor class

Stopped Study terminated due to insufficient evidence to support a positive benefit: risk profile in systemic lupus erythematosus patients.

Conditions

Interventions

Sponsor

Eli Lilly and Company

Collaborators